R. T. Alamo Ventures I, Inc.

Zynerba Pharmaceuticals, Inc.

Alltranz Inc.

Buzzz Pharmaceuticals Limited

Ptrl East, Inc.

Miroslaw Jerzy Golinski

Stefan Kwiatkowski

Audra Lynn Stinchcomb

Dana Carmel Hammell

Stan Lee Banks

Jeffrey Lynn Howard

Jeffery Lynn Howard

Josh Eldridge

Joseph Kupper

Guohua Li

Audra Lynn Strinchcomb

Dana Carmel Hammel

Jeffry Lynn Howard

Dand Carmel Hammell

Described herein arecannabidiol prodrugs used in pharmaceutical compositions as well asmicroneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.

Use of cannabidiol prodrugs in pharmaceutical compositions

An abuse deterrent transdermal patch comprising a multilaminate. The multilaminate can comprise a first layer comprising an opioid analgesic compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable pressure sensitive adhesive. The multilaminate can further comprise a second layer comprising an opioid antagonist, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adhesive. In addition, the multilaminate can further comprise a barrier layer disposed between the first and second layers.

Abuse deterrent opioid/opioid-antagonist transdermal patch

The present invention relates to a transdermal patch comprising oxymorphone. The present invention also relates to processes for the preparation of the transdermal patches defined herein, as well as to the use of these patches for the treatment of pain.

Oxymorphone transdermal patch

Described herein are &#x394;-THC prodrugs, methods of making &#x394;-THC prodrugs, formulations comprising &#x394;-THC prodrugs and methods of using &#x394;-THC. One embodiment described herein relates to the transdermal administration of a &#x394;-THC prodrug for treating and preventing diseases and/or disorders.

Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same

Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.

Use of cannabidiol prodrugs in topical and transdermal administration with microneedles

Described herein are abuse-resistant multi-layer transdermal patches comprising opioids and opioid prodrugs having a barrier layer located between the layer containing opioid or opioid prodrug and a layer containing an opioid antagonist or opioid antagonist prodrug.

Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists

Described herein are opioid prodrugs, methods of making opioid prodrugs, formulations comprising opioid prodrugs, and methods of using opioid prodrugs. One embodiment described herein relates to the transdermal administration of a buprenorphine prodrug in an abuse-resistant formulation for treating and preventing diseases and/or disorders.

Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs

Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.

Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same

The present invention describes methods for the stereoselective synthesis of heterocyclic enantiomers. The methods of the present invention incorporate the stereo-preferred oxidation of quinolone thiomethyl intermediates by optically active camphor based oxaziridines to provide R(+) or S(&#x2212;) quinolone methylsulfinyl derivatives.

Stereospecific enrichment of heterocyclic enantiomers

Compositions of the present invention comprise dichlorinated heterocyclic compounds, including dichloroflosequinan. The methods of the present invention also comprise the synthesis of dichloroflosequinan.

Dichlorinated heterocyclic compounds and methods of synthesis

Compositions of the present invention comprise fluorinated heterocyclic compounds, including monofluoroflosequinan and difluoroflosequinan. The methods of the present invention comprise the synthesis of monofluoroflosequinan and difluoroflosequinan.

Growing community of inventors

Lexington, KY, United States of America

Miroslaw Jerzy Golinski